SARS-CoV-2 proteome microarray for COVID-19 patient sera profiling

Dan-Yun Lai; He-Wei Jiang; Yang Li; Hai-Nan Zhang; Sheng-Ce Tao

doi:10.1016/j.xpro.2022.101238

SARS-CoV-2 proteome microarray for COVID-19 patient sera profiling

STAR Protoc. 2022 Feb 28;3(2):101238. doi: 10.1016/j.xpro.2022.101238. eCollection 2022 Jun 17.

Authors

Dan-Yun Lai¹, He-Wei Jiang¹, Yang Li², Hai-Nan Zhang¹, Sheng-Ce Tao¹

Affiliations

¹ Shanghai Center for Systems Biomedicine, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China.
² College of Life Science, Nankai University, Tianjin 300071, China.

Abstract

The immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteome is largely unknown. Here we describe a protocol for analyzing sera samples with SARS-CoV-2 proteome microarray. The proteins were expressed by either E. coli expression system or eukaryotic cell expression systems and obtained by affinity purification. The protocol includes microarray fabricating and sera profiling, which will be used to build an antibody response landscape for IgG and IgM. The protocol may help to facilitate a deeper understanding of immunity related to SARS-CoV-2. For complete details on the use and execution of this protocol, please refer to Li et al. (2021c).

Keywords: Biotechnology and bioengineering; Clinical Protocol; Health Sciences; Immunology; Protein Biochemistry; Protein expression and purification; Proteomics.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Viral
COVID-19*
Escherichia coli
Humans
Proteome
SARS-CoV-2*

Substances

Antibodies, Viral
Proteome